An AI pathology test that predicts BCG non-response in non-muscle-invasive bladder cancer using routine histology.

A prognostic pathology test that measures progression risk in metastatic hormone-sensitive prostate cancer from tumor biology.

A predictive pathology test that identifies patients likely to derive greater benefit from ARPI intensification alongside ADT.

An AI pathology test that estimates individualized high-grade recurrence and muscle-invasive progression risks from existing tumor specimens.

A predictive pathology test that identifies patients likely to benefit from adding docetaxel to ADT and ARPI therapy.

An AI pathology test that classifies chemotherapy preference to guide first-line treatment for advanced pancreatic cancer.